Mechanisms of mitoxantrone in multiple sclerosis–what is known?

[1]  H. Kornhuber,et al.  Treatment of multiple sclerosis with mitoxantrone , 2005, European Archives of Psychiatry and Clinical Neuroscience.

[2]  H. Hartung,et al.  Mitoxantrone (Novantrone®) in multiple sclerosis: new insights , 2004, Expert review of neurotherapeutics.

[3]  D. Goodin,et al.  The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis , 2003, Neurology.

[4]  H. Hartung,et al.  Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection. , 2003, Trends in pharmacological sciences.

[5]  C. Buhmann,et al.  Effects of Mitoxantrone on Multiple Sclerosis Patients’ Lymphocyte Subpopulations and Production of Immunoglobulin, TNF-alpha and IL-10 , 2003, European Neurology.

[6]  H. Hartung,et al.  Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial , 2002, The Lancet.

[7]  V. Perry,et al.  Axon pathology in neurological disease: a neglected therapeutic target , 2002, Trends in Neurosciences.

[8]  L. Steinman,et al.  Approved and Future Pharmacotherapy for Multiple Sclerosis , 2002, The neurologist.

[9]  H. Hartung,et al.  New concepts in the immunopathogenesis of multiple sclerosis , 2002, Nature Reviews Neuroscience.

[10]  C. Lucchinetti,et al.  Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. , 2001, Trends in molecular medicine.

[11]  K. Jain.  Evaluation of mitoxantrone for the treatment of multiple sclerosis , 2000, Expert opinion on investigational drugs.

[12]  Jeffrey A. Cohen,et al.  Multiple Sclerosis Therapeutics , 1999 .

[13]  B D Trapp,et al.  Axonal pathology in multiple sclerosis: relationship to neurologic disability. , 1999, Current opinion in neurology.

[14]  P. Queirolo,et al.  Mitoxantrone in elderly patients with advanced breast cancer: pharmacokinetics, marrow and peripheral hematopoietic progenitor cells. , 1999, Anticancer research.

[15]  D. Colomer,et al.  Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B‐chronic lymphocytic leukaemia cells , 1998, British journal of haematology.

[16]  A. Ballestrero,et al.  High-dose mitoxantrone with peripheral blood progenitor cell rescue: toxicity, pharmacokinetics and implications for dosage and schedule. , 1997, British Journal of Cancer.

[17]  C. Pozzilli,et al.  Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome , 1997, Journal of Neurology.

[18]  E. Cabanis,et al.  Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. , 1997, Journal of neurology, neurosurgery, and psychiatry.

[19]  R. Gonsette,et al.  Mitoxantrone immunotherapy in multiple sclerosis , 1996, Multiple sclerosis.

[20]  G. Houin,et al.  Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomas. , 1993, Cancer research.

[21]  Kuang Y. Chen,et al.  Pharmacokinetic and pharmacodynamic studies with mitoxantrone in the treatment of patients with nasopharyngeal carcinoma , 1992, Cancer.

[22]  R. Knobler,et al.  Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone. , 1987, Clinical immunology and immunopathology.

[23]  S. Levine,et al.  Regional suppression, therapy after onset and prevention of relapses in experimental allergic encephalomyelitis by mitoxantrone , 1986, Journal of Neuroimmunology.

[24]  S. Dejoy,et al.  Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function. , 1986, Journal of immunology.

[25]  S. Dejoy,et al.  Selective immunomodulation by the antineoplastic agent mitoxantrone. II. Nonspecific adherent suppressor cells derived from mitoxantrone-treated mice. , 1986, Journal of immunology.

[26]  S. Levine,et al.  Suppression of experimental allergic encephalomyelitis by mitoxantrone. , 1985, Clinical immunology and immunopathology.

[27]  R. Wallace,et al.  Molecular and biochemical pharmacology of mitoxantrone. , 1983, Cancer treatment reviews.

[28]  I. Smith,et al.  Mitoxantrone (novantrone): a review of experimental and early clinical studies. , 1983, Cancer treatment reviews.